Disc Medicine, Inc. (NASDAQ:IRON) Shares Sold by Rafferty Asset Management LLC

Rafferty Asset Management LLC decreased its stake in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 24.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,749 shares of the company's stock after selling 8,977 shares during the period. Rafferty Asset Management LLC owned approximately 0.09% of Disc Medicine worth $1,759,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in IRON. Sterling Capital Management LLC lifted its position in shares of Disc Medicine by 798.4% during the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock valued at $36,000 after acquiring an additional 503 shares during the period. Tower Research Capital LLC TRC raised its holdings in Disc Medicine by 47.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock worth $52,000 after purchasing an additional 266 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in Disc Medicine during the fourth quarter worth $235,000. Fiduciary Trust Co purchased a new stake in Disc Medicine during the fourth quarter worth $257,000. Finally, Bayesian Capital Management LP acquired a new stake in Disc Medicine in the fourth quarter valued at $285,000. Hedge funds and other institutional investors own 83.70% of the company's stock.

Disc Medicine Stock Down 1.4%

Shares of NASDAQ:IRON traded down $0.67 during midday trading on Monday, reaching $47.37. The company's stock had a trading volume of 132,011 shares, compared to its average volume of 347,391. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -11.90 and a beta of 0.77. The business has a 50 day moving average price of $45.75 and a 200 day moving average price of $54.64. Disc Medicine, Inc. has a 1 year low of $30.82 and a 1 year high of $68.73.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.03). Sell-side analysts anticipate that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Disc Medicine news, Director Mona Ashiya sold 83,182 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $54.45, for a total transaction of $4,529,259.90. Following the completion of the sale, the director now owns 194,209 shares of the company's stock, valued at approximately $10,574,680.05. The trade was a 29.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider William Jacob Savage sold 6,677 shares of the company's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $50.04, for a total value of $334,117.08. Following the sale, the insider now owns 59,721 shares of the company's stock, valued at $2,988,438.84. This represents a 10.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 349,510 shares of company stock valued at $18,936,535. Insiders own 4.24% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on IRON. Morgan Stanley reiterated an "overweight" rating and issued a $85.00 price objective on shares of Disc Medicine in a research report on Friday, March 7th. Scotiabank increased their price target on shares of Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a research report on Monday, March 3rd. Cantor Fitzgerald raised their price objective on shares of Disc Medicine from $99.00 to $132.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 18th. TD Cowen assumed coverage on Disc Medicine in a research note on Thursday, February 27th. They issued a "buy" rating on the stock. Finally, BMO Capital Markets increased their price objective on Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a research note on Monday, May 12th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Disc Medicine presently has an average rating of "Buy" and an average price target of $98.80.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.